Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018
Management to host conference call
WALTHAM, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2018 on Thursday, May 3, 2018. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 8885379. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event for 30 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva's proprietary compounds include: roluperidone (MIN-101), in Phase 3 clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922) in Phase 2b clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by the Board of Directors18.4.2024 17:46:00 CEST | Press release
Annual General Meeting 2024: Tecan shareholders endorse all motions proposed by the Board of Directors Increase in the dividend from CHF 2.90 to CHF 3.00 per share Monica Manotas elected as additional independent member of the Board of DirectorsLukas Braunschweiler, Myra Eskes, Oliver Fetzer, Matthias Gillner, Karen Huebscher, Christa Kreuzburg and Daniel R. Marshak re-elected as members of the Board of DirectorsLukas Braunschweiler confirmed by shareholders as Chair of the BoardMyra Eskes, Oliver Fetzer, Christa Kreuzburg and Daniel R. Marshak confirmed as members of the Compensation CommitteeVarious amendments to the Articles of Incorporation approvedAll proposals relating to compensation approvedApproval of the Report on Non-Financial Matters 2023 (Sustainability Report) Männedorf, Switzerland, April 18, 2024 – The Annual General Meeting of the Tecan Group (SIX Swiss Exchange: TECN) endorsed all motions proposed by the Board of Directors. Shareholders approved the Annual Report, the
Ipsos: Continued momentum in Q118.4.2024 17:45:30 CEST | Press release
Continued momentum in Q1 Total growth: 4.8% Organic growth: 4.5% Paris, 18 April 2024 – Ipsos, one of the world’s leading market research companies, achieves a solid first quarter, with a revenue of €557.5m. Revenue (€m)20242023202220212020Q1557.5532.0547.8466.3428.7Q2555.1 574.0527.0357.3Q3588.0 601.5526.3468.6Q4714.7 682.1627.1582.9Total2,389.82,405.32,146.71,837.4 This income level confirms the continuation of the Group’s sustained growth. First-quarter growth stands at 4.8%, including 4.5% organic growth, 2.7% scope effect, and -2.4% of adverse currency effects. Ben Page, CEO of Ipsos, states: “The start of the year is encouraging. It demonstrates our ability to deliver sustainable solid growth combined with a high level of operating margin. Our geographical and sectoral diversity, which provides greater resilience, combined with the talent of our 20,000 employees, are major advantages for continuing our development. In a geopolitical environment that remains uncertain, we confirm
Q1 2024 Trading Statement18.4.2024 17:40:47 CEST | Press release
COMPANY ANNOUNCEMENT NO 12/2024 - April 18, 2024 Strong business momentum continued into 2024 – organic EBIT growth guidance raised Statement by Royal Unibrew’s CEO, Lars Jensen: “The first quarter has marked a strong start to the year. The business momentum we built throughout 2023 has continued into 2024. The continued strong performance of our markets in Northern Europe, combined with a normalized Italian On-Trade beer channel and a strong rebound in our International segment, drove solid organic volume growth of 6% in the first quarter. Strong value management efforts from our organization across all categories ensured organic net revenue growth of 10% in the first quarter. Going into 2024, we further intensified our focus on delivering the efficiency improvements after some turbulent years with unprecedented high inflation, strong volume growth and a series of acquisitions. This increased focus starts to yield results towards the end of the first quarter. Vrumona has now begun pro
Sdiptech AB (publ) - Notice of annual general meeting 202418.4.2024 17:40:00 CEST | Press release
Press release 18 April 2024, 17:40 NOTICE OF ANNUAL GENERAL MEETING 2024 OF SDIPTECH AB (PUBL) The shareholders of Sdiptech AB (publ), reg. no. 556672-4893 (the "Company") are hereby convened to the Annual General Meeting on 22 May 2024, at IVA (Royal Swedish Academy of Engineering Sciences), Grev Turegatan 16, 114 46 i Stockholm. The Board has decided, with the support of § 12 of the Company's Articles of Association, that those shareholders who are unable or unwilling to physically participate in the meeting shall be able to submit their votes in advance by so-called postal voting. More information about it below. General requirements for participation Shareholders who wish to participate in the meeting, regardless of whether this is done physically or by postal vote, must be entered in the share register kept by Euroclear Sweden AB as of the record date, 14 May 2024. Shareholders with nominee-registered shares must temporarily have the shares re-registered in their own name as of th
Sdiptech AB (publ) - Kallelse till årsstämma 202418.4.2024 17:40:00 CEST | Pressemelding
Pressmeddelande 18 april 2024, 17:40 KALLELSE TILL ÅRSSTÄMMA 2024 I SDIPTECH AB (PUBL) Aktieägarna i Sdiptech AB (publ), org. nr 556672-4893 (”Bolaget”), kallas härmed till årsstämma den 22 maj 2024 klockan 16.00, på IVA (Ingenjörsvetenskapsakademien), Grev Turegatan 16, 114 46 i Stockholm. Styrelsen har beslutat, med stöd av § 12 i Bolagets bolagsordning, att de aktieägare som inte kan eller vill delta fysiskt vid stämman ska kunna skicka in sina röster i förväg genom så kallad poströstning. Mer information om det nedan. Generellt krav för deltagande Aktieägare som önskar delta i stämman, oavsett om så sker fysiskt eller genom poströstning, måste vara upptagen i den av Euroclear Sweden AB förda aktieboken per avstämningsdagen den 14 maj 2024. Aktieägare med förvaltarregistrerade aktier måste tillfälligt låta omregistrera aktierna i eget namn per avstämningsdagen och kontakt bör tas med banken/förvaltaren i god tid innan. Förvaltaren har möjlighet att göra sådan rösträttsregistrering r